Hermetica Superfood Encyclopedia
The Short Answer
Vao Vai contains indoquinoline alkaloids (cryptolepine, quindoline, 11-methoxy-quindoline), phenolics (epicatechin, scopoletin), and flavonoids (kaempferol) that mediate analgesic and anti-inflammatory effects through nitric oxide inhibition and free radical scavenging. Its n-hexane extract inhibits nitric oxide production with an IC50 of 52.16 μg/mL and protein denaturation with an IC50 of 146.03 μg/mL in vitro, supporting its traditional Samoan use for pain relief.
CategoryHerb
GroupPacific Islands
Evidence LevelPreliminary
Primary KeywordVao Vai benefits
Vao Vai — botanical close-up
Health Benefits
**Pain Relief (Analgesic)**
The plant's anti-inflammatory alkaloids and phenolics suppress inflammatory mediators including nitric oxide, providing a mechanistic basis for its traditional Samoan use as a pain remedy; IC50 for NO inhibition is 52.16 μg/mL in n-hexane extract.
**Anti-Inflammatory Activity**: Protein denaturation inhibition (IC50 146
03 μg/mL) by the n-hexane extract indicates membrane-stabilizing and anti-inflammatory properties, analogous to the mechanism of non-steroidal anti-inflammatory agents.
**Antioxidant Protection**
The ethyl acetate extract scavenges DPPH radicals (EC50 380.5 μg/mL) and chelates ferrous ions (EC50 263.4 μg/mL), with epicatechin (1.3 mg/g) identified as a primary contributor to oxidative stress reduction.
**Cardiovascular Support (Vasorelaxation)**
Indoquinoline alkaloids, specifically quindoline and 11-methoxy-quindoline isolated from aerial parts, relax vascular smooth muscle and are proposed to underpin hypotensive effects documented in Brazilian folk medicine use.
**Potential Anticancer Activity**
The n-hexane extract inhibits HepG2 hepatocellular carcinoma cells by 47.82% and SNU-1 gastric cancer cells by 68.52% at 100 μg/mL; the ethyl acetate extract (300 μg/mL) induces 34% apoptosis in HepG2 cells via Bax gene upregulation and an elevated Bax/Bcl-2 ratio.
**Cholinesterase Inhibition**
The n-hexane extract inhibits acetylcholinesterase (AChE) by 58.55% at 100 μg/mL in vitro, suggesting potential relevance to cognitive and neuromuscular conditions, though no human trials have examined this application.
**Antimicrobial and Adaptogenic Traditional Uses**
Traditional Ayurvedic preparations using the plant as 'Bala' attribute nerve-tonic, anti-inflammatory, and anti-rheumatic properties; phytoconstituents including saponins, tannins, and terpenoids have been qualitatively confirmed and may collectively contribute to these effects.
Origin & History
Natural habitat
Sida rhombifolia is a pantropical weed native to tropical and subtropical regions of the Americas, now widely naturalized across Africa, Asia, the Pacific Islands, and Australia. In Samoa and other Pacific Island nations, it grows abundantly in disturbed soils, roadsides, and agricultural margins, thriving in full sun and poor soils with minimal cultivation. The plant is not formally cultivated but is harvested wild; its aerial parts and roots are the primary material used in traditional preparations.
“Sida rhombifolia has a deep and geographically diverse history of traditional use spanning at least three major ethnomedicinal traditions. In Samoa and Pacific Island cultures, the plant—known as 'Vao Vai'—is employed as a remedy for pain and physical discomfort, with preparations typically involving the aerial parts. In Ayurvedic medicine, it is classified as 'Bala' (meaning strength) and holds a prominent place in classical formulations such as Balarishta and KsheeraBala Thailam, prescribed for conditions ranging from rheumatism and neurological disorders to general debility. In Brazilian folk medicine, regional names 'matapasto' and 'guanxuma' reflect widespread peasant and indigenous use for hypertension, diabetes, and gout, with these applications later prompting pharmacological investigation of the plant's vasoactive alkaloids and hypoglycemic potential.”Traditional Medicine
Scientific Research
The existing evidence base for Sida rhombifolia consists exclusively of in vitro cell-based assays and limited in vivo toxicity screens, with no published randomized controlled trials or human clinical studies of any phase. In vitro studies have quantified cytotoxicity against HepG2 and SNU-1 cancer cell lines, antioxidant capacity via DPPH and metal chelation assays, AChE inhibition, and NO suppression in macrophage models, providing preliminary mechanistic data but no translatable human efficacy evidence. Qualitative phytochemical screening has confirmed the presence of alkaloids, flavonoids, tannins, saponins, terpenoids, and quinones across multiple studies, with HPLC quantification limited to epicatechin at 1.3 mg/g in ethyl acetate extract. The overall evidence base is preclinical in nature, rated low-to-moderate quality by contemporary clinical evidence standards, and pharmacokinetic, bioavailability, and dose-translation studies are entirely absent.
Preparation & Dosage
Traditional preparation
**Traditional Aqueous Decoction (Samoan/Pacific)**
Aerial parts or whole plant boiled in water; specific volumes and concentrations are not standardized in scientific literature; used topically or orally for pain.
**Ayurvedic Oil Preparation (KsheeraBala Thailam)**
Roots processed in milk and sesame oil base; used topically for neurological and musculoskeletal conditions in classical Indian medicine; no modern dosage equivalence established.
**Brazilian Folk Preparation**
Aerial parts prepared as tea or decoction ('matapasto/guanxuma') for hypertension and diabetes; no validated dose or standardization exists.
**Research Extract Concentrations (In Vitro Reference Only)**
n-Hexane and ethyl acetate extracts tested at 100–300 μg/mL in cell-based assays; these concentrations are not translatable to human supplement doses without pharmacokinetic data.
**Standardized Supplement Forms**
No commercially standardized capsules, tinctures, or extracts with defined alkaloid or flavonoid content are established in scientific or regulatory literature as of current evidence.
**Timing Notes**
No clinical data exists to guide dosing frequency, timing relative to meals, or duration of use.
Nutritional Profile
Sida rhombifolia is not consumed as a dietary staple and does not have a characterized macronutrient or micronutrient profile in the nutritional science literature. Its primary bioactive constituents identified analytically include: indoquinoline alkaloids (cryptolepine, quindoline, 11-methoxy-quindoline, quindolinone) in aerial parts with no bulk concentration data; phenolic compounds including scopoletin, scoporone, ethoxy-ferulate, and epicatechin (quantified at 1.3 mg/g in ethyl acetate extract); flavonoids including kaempferol and kaempferol-3-O-β-D-glycosyl-6″-α-L-rhamnose; fatty acids including palmitic acid and linoleic acid in the n-hexane fraction; phytosterol γ-sitosterol; and tannins and saponins confirmed qualitatively. Bioavailability of these compounds from traditional aqueous or oil-based preparations has not been measured in any pharmacokinetic study, and matrix interactions affecting absorption remain uncharacterized.
How It Works
Mechanism of Action
The n-hexane fraction of Sida rhombifolia inhibits lipopolysaccharide-induced nitric oxide production in macrophage-like systems, likely by suppressing inducible nitric oxide synthase (iNOS) activity, as reflected by an IC50 of 52.16 μg/mL; protein denaturation inhibition at IC50 146.03 μg/mL further supports membrane-stabilizing, anti-inflammatory action. Indoquinoline alkaloids—quindoline, 11-methoxy-quindoline, and cryptolepine—are proposed to relax vascular smooth muscle through calcium channel modulation or direct interaction with adrenergic pathways, contributing to hypotensive and vasodilatory effects. In cancer cell lines, the ethyl acetate extract triggers the intrinsic apoptotic pathway by upregulating pro-apoptotic Bax gene expression and increasing the Bax/Bcl-2 ratio in HepG2 cells, indicating mitochondria-mediated cell death. Acetylcholinesterase inhibition by the n-hexane fraction (58.55% at 100 μg/mL) suggests interference with cholinergic neurotransmission at the enzyme active site, a mechanism shared with several clinically used cognitive agents; however, specific receptor binding constants and downstream signaling cascades remain to be characterized in formal mechanistic studies.
Clinical Evidence
No human clinical trials have been conducted on Sida rhombifolia or its standardized extracts for any indication, including pain, inflammation, hypertension, or cancer. All quantified outcomes originate from in vitro assays on isolated cell lines or cell-free radical scavenging systems, meaning effect sizes such as IC50 and EC50 values cannot be directly extrapolated to human therapeutic doses without pharmacokinetic bridging studies. In vivo assays (e.g., brine shrimp lethality tests) suggest low acute toxicity at tested concentrations, but systemic safety in mammals at therapeutic-range doses has not been rigorously established. Confidence in clinical efficacy for any condition is very low; traditional use in Samoa, Brazil, and Ayurvedic medicine provides ethnopharmacological hypothesis generation but not clinical validation.
Safety & Interactions
Sida rhombifolia demonstrates low acute toxicity in preliminary in vivo assays including brine shrimp lethality tests, and tested extract concentrations have not produced overt cytotoxicity at pharmacologically relevant doses in available studies. However, the plant contains cytotoxic alkaloids (cryptolepine, quindoline) that inhibit cancer cell lines at 100 μg/mL, warranting caution for individuals undergoing chemotherapy or targeted cancer therapies due to potential pharmacodynamic interactions. No formal drug interaction studies exist; given the AChE inhibitory activity of the n-hexane extract, theoretical interactions with cholinergic medications (e.g., donepezil, rivastigmine) and anticholinergic drugs cannot be excluded. Comprehensive safety data in pregnant women, lactating mothers, pediatric populations, and individuals with hepatic or renal impairment is entirely absent, and use in these groups should be avoided until adequate human safety data is generated.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Sida rhombifoliaArrowleaf SidaBala (Ayurvedic)MatapastoGuanxumaCountry MallowVao Vai
Frequently Asked Questions
What is Vao Vai used for in Samoan traditional medicine?
In Samoan traditional medicine, Vao Vai (Sida rhombifolia) is primarily used as a remedy for pain and physical discomfort, with preparations typically made from the aerial parts of the plant as decoctions or topical applications. The plant's analgesic and anti-inflammatory activity is supported by in vitro evidence showing inhibition of nitric oxide production (IC50 52.16 μg/mL) and protein denaturation (IC50 146.03 μg/mL) in the n-hexane extract. No human clinical trials have confirmed these traditional applications.
What are the main bioactive compounds in Sida rhombifolia?
Sida rhombifolia contains several classes of bioactive compounds, including indoquinoline alkaloids (cryptolepine, quindoline, 11-methoxy-quindoline, quindolinone), phenolic acids and coumarins (scopoletin, scoporone, ethoxy-ferulate), flavonoids (kaempferol, kaempferol-3-O-β-D-glycosyl-6″-α-L-rhamnose), and the flavan-3-ol epicatechin, which has been quantified at 1.3 mg/g in the ethyl acetate extract. The n-hexane fraction also contains fatty acids (palmitic acid, linoleic acid) and the phytosterol γ-sitosterol. The alkaloids, particularly cryptolepine and quindoline, are considered the most pharmacologically significant compounds based on current research.
Is Sida rhombifolia safe to use?
Preliminary in vivo toxicity assays, including brine shrimp lethality tests, suggest low acute toxicity for Sida rhombifolia extracts at tested concentrations. However, the plant contains cytotoxic alkaloids such as cryptolepine that inhibit cancer cell growth in vitro, and no formal human safety studies, drug interaction trials, or toxicological assessments in vulnerable populations (pregnant women, children, people with liver or kidney disease) have been conducted. Until adequate human safety data is available, use should be approached with caution and only under guidance of a qualified healthcare practitioner.
Does Sida rhombifolia have anticancer properties?
In vitro studies show that the n-hexane extract of Sida rhombifolia inhibits HepG2 hepatocellular carcinoma cells by 47.82% and SNU-1 gastric cancer cells by 68.52% at a concentration of 100 μg/mL, while the ethyl acetate extract (300 μg/mL) induces 34% apoptosis in HepG2 cells via upregulation of pro-apoptotic Bax gene expression and an elevated Bax/Bcl-2 ratio. These results are promising at the preclinical level but have not been replicated in animal tumor models or human clinical trials. Sida rhombifolia cannot be recommended as a cancer treatment based on current evidence, and individuals with cancer should consult their oncologist before use.
What is the difference between Sida rhombifolia and Bala in Ayurvedic medicine?
In Ayurvedic medicine, Sida rhombifolia is classified under the name 'Bala' (Sanskrit for strength) and is one of several Sida species used interchangeably in classical formulations. It is a key ingredient in preparations such as KsheeraBala Thailam (an oil used for neurological and musculoskeletal conditions) and Balarishta (a fermented tonic). Ayurvedic use attributes nerve-tonic, anti-inflammatory, analgesic, and anti-rheumatic properties to Bala, which partially aligns with modern phytochemical findings on its alkaloid and flavonoid content, though direct comparative pharmacological studies between the Ayurvedic preparation context and isolated extract research are limited.
How does Sida rhombifolia's pain-relieving mechanism differ from conventional NSAIDs?
Sida rhombifolia relieves pain through nitric oxide (NO) inhibition and suppression of inflammatory mediators via its alkaloid and phenolic compounds, rather than through COX enzyme inhibition like NSAIDs. Studies show the n-hexane extract achieves 50% NO inhibition at 52.16 μg/mL, providing a distinct biochemical pathway that may reduce gastrointestinal side effects associated with traditional pain medications. This mechanism makes it a potential complementary option for individuals seeking alternative analgesic approaches.
What extraction method of Sida rhombifolia shows the strongest anti-inflammatory activity?
The n-hexane extract of Sida rhombifolia demonstrates significant anti-inflammatory potency, with an IC50 of 146.03 μg/mL for protein denaturation inhibition—a key marker of anti-inflammatory efficacy. This solvent extraction captures the plant's alkaloid and phenolic compounds more effectively than water-based preparations. N-hexane extraction targets lipophilic bioactive constituents responsible for the plant's traditional pain and inflammation relief applications.
Is Sida rhombifolia effective for chronic inflammatory conditions, and what does the research indicate?
Research supports Sida rhombifolia's use for chronic inflammatory conditions through demonstrated inhibition of inflammatory mediators and protein denaturation at measurable concentrations. The plant's anti-inflammatory alkaloids and phenolics provide a mechanistic basis for its historical Samoan use in treating persistent pain and inflammation. However, most evidence comes from in vitro studies; larger clinical trials are needed to establish optimal dosing and efficacy benchmarks for specific inflammatory conditions in humans.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w vao-vai-sida-rhombifolia curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
